Anastasis enhances metastasis and chemoresistance of colorectal cancer cells through upregulating cIAP2/NFκB signaling

Cell Death Dis. 2023 Jun 30;14(6):388. doi: 10.1038/s41419-023-05916-8.

Abstract

Chemotherapy is a common strategy to treat cancer. However, acquired resistance and metastasis are the major obstacles to successful treatment. Anastasis is a process by which cells survive executioner caspase activation when facing apoptotic stress. Here we demonstrate that colorectal cancer cells can undergo anastasis after transient exposure to chemotherapeutic drugs. Using a lineage tracing system to label and isolate cells that have experienced executioner caspase activation in response to drug treatment, we show that anastasis grants colorectal cancer cells enhanced migration, metastasis, and chemoresistance. Mechanistically, treatment with chemotherapeutic drugs induces upregulated expression of cIAP2 and activation of NFκB, which are required for cells to survive executioner caspase activation. The elevated cIAP2/NFκB signaling persists in anastatic cancer cells to promote migration and chemoresistance. Our study unveils that cIAP2/NFκB-dependent anastasis promotes acquired resistance and metastasis after chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Caspases
  • Cell Death Reversal*
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Drug Resistance, Neoplasm
  • Humans
  • NF-kappa B

Substances

  • NF-kappa B
  • Caspases